Page Contents
We have included a GRI Reference Table in this Annual Review as a reference tool to help readers more readily locate relevant information across Pfizer's web-based resources. Pfizer continues to evaluate our approach to non-financial reporting, including reference to several existing, globally recognized external frameworks – for more information, on our global reporting framework,click here.
| GRI Indicator | Description | Reference | United Nations (UN) Sustainable Development Goals (SDGs) |
|---|---|---|---|
| GRI 102: General Disclosures 2019 | |||
| Organizational Profile | |||
| 102-1 | Name of the organization |
Pfizer Inc.
|
|
| 102-2 | Activities, brands, products and services |
Chairman & CEO Letter
|
|
| 102-3 | Location of headquaters |
New York, New York (U.S.)
|
|
| 102-4 | Location of operations |
Pfizer Global Sites
|
|
| 102-5 | Ownership and legal form |
Corporate and Shareholder Information
|
|
| 102-6 | Markets served |
Chairman & CEO Letter
|
|
| 102-7 | Scale of the organization |
Chairman & CEO Letter
|
|
| 102-9 | Supply chain |
EHS Supply Chain
|
Goal9
Goal12 |
| 102-11 | Precautionary Principle or approach |
Pfizer manages and reports on our risks and impacts in consideration of the precautionary principle.
|
|
| 102-12 | External initiatives |
Governance & Ethics
|
|
| 102-13 | Membership of associations |
Lobbying and Political Contributions
|
|
| Strategy | |||
| 102-14 | Statement from senior decision-maker |
Chairman & CEO Letter
|
|
| 102-15 | Key impacts, risks, and opportunities |
Governance and Ethics
|
|
| Ethics and Integrity | |||
| 102-16 | Values, principles, standards and norms of behavior |
Pfizer Compliance
|
Goal16
|
| 102-17 | Mechanisms for advice and concerns about ethics |
Governance and Ethics
|
|
| Governance | |||
| 102-18 | Governance structure |
Governance and Ethics
|
|
| 102-19 | Delegating authority |
Board Committees and Charters
|
|
| 102-20 | Executive-level responsibility for economic, environmental and social topics |
Meeting Our Environmental Sustainability Goals
|
Goal3
|
| 102-21 | Consulting stakeholders on economic, environmental and social topics |
Meeting Our Environmental Sustainability Goals
|
|
| 102-22 | Composition of the highest governance body and its committees |
Board of Directors
Board Committees and Charters |
Goal16
|
| 102-23 | Chair of the highest governance body |
The Pfizer Board: Board Policies
SEC Filings |
Goal16
|
| 102-24 | Nominating and selecting the highest governance body |
Corporate Governance Principles
|
Goal5
Goal16 |
| 102-25 | Conflicts of interest |
The Pfizer Board: Board Policies
|
Goal16
|
| 102-26 | Role of highest governance body in setting purpose, values and strategy |
Corporate Governance Principles
|
|
| 102-27 | Collective knowledge of highest governance body |
Corporate Governance Principles
|
|
| 102-28 | Evaluating the highest governance body's performance |
Corporate Governance Principles
|
|
| 102-29 | Identifying and managing economic, environmental and social impacts |
Board Committees and Charters
Governance and Ethics |
Goal16
|
| 102-30 | Effectiveness of risk management processes |
Board Committees and Charters
|
|
| 102-31 | Review of economic, environmental, and social topics |
Board Committees and Charters
|
|
| 102-32 | Highest governance body's role in sustainability reporting |
About this Review
Board Committees and Charters |
|
| 102-36 | Process for determining remuneration |
Financials: Annual Reports
|
|
| 102-38 | Annual total compensation ratio |
Financials: Annual Reports
|
|
| Stakeholder Engagement | |||
| 102-40 | List of stakeholder groups |
Stakeholder Services
|
|
| 102-43 | Approach to stakeholder engagement |
Transparency
|
|
| Reporting Practice | |||
| 102-45 | Entities included in the consolidated financial statements |
About this Review
|
|
| 102-46 | Defining report content and topic Boundaries |
About this Review
|
|
| 102-47 | List of material topics |
About this Review
|
|
| 102-49 | Changes in reporting |
No changes in reporting since 2016 report
|
|
| 102-50 | Reporting period |
About this Review
|
|
| 102-51 | Date of most recent report |
March 13, 2020
|
|
| 102-52 | Reporting cycle |
We report on an annual basis
|
|
| 102-53 | Contact point for questions regarding the report |
Frank Briamonte, Vice President, Executive Communications
|
|
| 102-55 | GRI content index |
GRI Reference Table
|
|
| Material Topics Economic | |||
| GRI 103: Management Approach 2019 | |||
| 103-1 | Explanation of the material topic and its Boundary |
About this Review
|
|
| 103-2 | The management approach and its components |
Product Stewardship
|
|
| 103-3 | Evaluation of the management approach |
Product Stewardship
|
|
| Economic Performance | |||
| 201-1 | Direct economic value generated and distributed |
Our Performance
|
|
| Indirect Economic Impacts | |||
| 203-1 | Infrastructure investments and services supported |
Individual Voices
|
|
| 203-2 | Significant indirect economic impacts |
Market Context: Understanding the External Environment
Patient Focus Includes Mitigating the Environmental Impact of Manufacturing Our Performance |
Goal1
Goal3 Goal8 Goal10 |
| Procurement Practices | |||
| 204-1 | Proportion of spending on local suppliers |
Ethics and Compliance
|
Goal12
|
| Anti-Corruption | |||
| 205-1 | Operations assessed for risks related to corruption |
Pfizer Compliance
|
Goal16
|
| Environmental | |||
| Water | |||
| 303-2 | Management of water discharge-related impacts |
Our Performance
|
Goal6
|
| 303-3 | Water withdrawal |
Our Performance
|
Goal6
|
| Emissions | |||
| 305-1 | Direct (Scope 1) GHG emissions |
Our Performance
|
Goal13
|
| 305-2 | Energy indirect (Scope 2) GHG emissions |
Goal13
|
|
| Effluents and Waste | |||
| 306-2 | Waste by type and disposal method |
Our Performance
|
Goal12
|
| Supplier Environmental Assessment | |||
| 308-2 | Negative environmental impacts in the supply chain and actions taken |
Our Performance
|
Goal12
|
| Social | |||
| Occupational Health and Safety | |||
| 403-2 | Types of injury and rates of injury, occupational diseases, lost days and absenteeism, and number of work-related fatalities |
Our Performance
|
Goal3
Goal8 |
| 403-9 | Work-related injuries |
Our Performance
|
Goal3
Goal8 |
| Training and Education | |||
| 404-1 | Average hours of training per year, per employee |
Our Culture
|
Goal4
Goal5 Goal8 |
| 404-2 | Programs for upgrading employee skills and transition assistance programs |
Our Culture
|
Goal8
|
| Non-Discrimination | |||
| 406-1 | Incidents of discrimination and corrective actions taken |
Our Culture
|
Goal5
Goal8 Goal16 |
| Human Rights Assessment | |||
| 412-2 | Employee training on human rights policies or procedures |
Human Rights Statement
|
|
| Local Communities | |||
| 413-1 | Operations with local community engagement, impact assessments and development programs |
Living Our Purpose
|
Goal3
Goal4 Goal5 Goal6 Goal7 Goal17 |
| Public Policy | |||
| 415-1 | Political contributions |
Corporate and Shareholder Information
|
Goal16
|
| Customer Privacy | |||
| 418-1 | Substantiated complaints concerning breaches of customer privacy and losses of customer data |
How We Conduct Clinical Trials
|
Goal16
|
Reference
| *Based on "SDG Compass: Linking the SDGs and GRI," as available on the GRI website’s resource library. Click here to view. |
